Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CP8N
|
|||
| Drug Name |
Silmitasertib
|
|||
| Synonyms |
CX-4945; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; W-204393
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 1/2 | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Investigative | [2], [3] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H12ClN3O2
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4
|
|||
| InChI |
1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)
|
|||
| InChIKey |
MUOKSQABCJCOPU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1009820-21-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN casein kinase II (CSK2) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02128282) Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma. U.S. National Institutes of Health. | |||
| REF 2 | News report, company report or official report of Senhwa Biosciences, Inc. Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy. 2020 March 31. | |||
| REF 3 | Casein Kinase 2 Is Linked to Stress Granule Dynamics through Phosphorylation of the Stress Granule Nucleating Protein G3BP1. Mol Cell Biol. 2017 Feb 1;37(4). pii: e00596-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.